Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- American Association of Medical Colleges (1)
- Bill C-17 (1)
- Conflict of Interest (1)
- Drug Manufacture (1)
- Ethics (1)
-
- Food and Drugs Act (1)
- Health Canada (1)
- Health Professionals Regulation (1)
- Market Exclusivity (1)
- Medical Education (1)
- Nova Scotia Regulated Health Professionals Network (1)
- Orphan Drug (1)
- Patents (1)
- Patient Safety (1)
- Pharmaceutical Policy (1)
- Physician Payment Sunshine Act (1)
- Physician-Industry Relationships (1)
- Rare Disease (1)
- Recalling Drugs (1)
- Self-Regulation (1)
- Speaker Bureau (1)
- Thalidomide (1)
- Voluntary Legislative Processes (1)
Articles 1 - 4 of 4
Full-Text Articles in Law
Legislating Interprofessional Regulatory Collaboration In Nova Scotia, William Lahey Prof.
Legislating Interprofessional Regulatory Collaboration In Nova Scotia, William Lahey Prof.
Articles, Book Chapters, & Popular Press
To shift health professions regulation from traditional to ‘collaborative’ self-regulation, Nova Scotia has adopted legislation which will: make all self-regulating health professions members of the Regulated Health Professions Network; mandate the Network to facilitate voluntary collaboration among its members; and enable regulators to work together on investigations of patient complaints, to adjust scopes of practice on an ongoing basis and to adjudicate appeals of unsuccessful applicants for registration. The goals are to give health professions regulation the capacity to enable and support the functioning of interprofessional teams. The legislation was adopted primarily for two reasons: collaborative development and unanimous support …
The Speakers’ Bureau System: A Form Of Peer Selling, Lynette Reid, Matthew Herder
The Speakers’ Bureau System: A Form Of Peer Selling, Lynette Reid, Matthew Herder
Articles, Book Chapters, & Popular Press
Physicians need to stay abreast of information about emerging drugs and devices, but the time pressures of clinical practice may limit their ability to do so independently. The companies that manufacture and sell these products have the resources and the motivation to “educate” physicians but cannot be expected to distinguish their marketing goals from physicians’ educational needs. Physicians’ professional associations and regulatory bodies, as well as medical journal publishers and editors, drug and device regulatory agencies, and academic medical institutions, have long debated their respective roles and responsibilities in ensuring the safety, efficacy, and probity of prescribing in light of …
When Everyone Is An Orphan: Against Adopting A Us-Styled Orphan Drug Policy In Canada, Matthew Herder
When Everyone Is An Orphan: Against Adopting A Us-Styled Orphan Drug Policy In Canada, Matthew Herder
Articles, Book Chapters, & Popular Press
Putting aside whether diseases that affect only small numbers of people ("rare diseases") should be prioritized over diseases that are otherwise orphaned, in this paper I argue that a new approach to rare, orphan diseases is needed. The current model, first signaled by the United States’ Orphan Drug Act and subsequently emulated by several other jurisdictions, relies on a set of open-ended criteria and market-based incentives in order to define and encourage drug therapies for rare, orphan diseases. Given a) the biopharmaceutical industries’ growing interest in orphan diseases, b) progress in the sphere of personalized medicines enabling more and more …
Regulating Prescription Drugs For Patient Safety: Does Bill C-17 Go Far Enough?, Matthew Herder, Elaine Gibson, Janice Graham, Joel Lexchin, Barbara Mintzes
Regulating Prescription Drugs For Patient Safety: Does Bill C-17 Go Far Enough?, Matthew Herder, Elaine Gibson, Janice Graham, Joel Lexchin, Barbara Mintzes
Articles, Book Chapters, & Popular Press
Canada was the last developed country in the world to remove thalidomide from the market, and doing so required an Act of Parliament. At the request of Health Canada’s then Food and Drug Directorate, thalidomide’s two manufacturers voluntarily withdrew the drug from the market on Mar. 2, 1962. However, most of the drug’s distribution was in the form of free samples to medical professionals, which the directorate had no legal authority to control. Therefore, to avoid similar situations in the future and to stop sales of thalidomide, on Dec. 4, 1962, the Parliament of Canada amended the Food and Drugs …